Sanofi, Regeneron loses patent challenge to Amgen cholesterol drug Repatha
Sanofi and Regeneron had stipulated that if the two Amgen patents were valid, their jointly developed cholesterol drug Praluent infringed them.
U.S: Biotech company Amgen Inc said on Monday a U.S. jury confirmed the validity of patents on its cholesterol drug Repatha, rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA.
Sanofi and Regeneron had stipulated that if the two Amgen patents were valid, their jointly developed cholesterol drug Praluent infringed them.
Amgen Chief Executive Robert Bradway said in a statement that the company was "thankful that the jury weighed the evidence carefully and recognized the validity of Amgen's patents."
Regeneron and Sanofi said in a statement they disagreed with aspects of the ruling and would seek to have it overturned.
"We will continue to vigorously defend our positions against Amgen's overly broad patent claims," Joseph LaRosa, Regeneron's general counsel, said in the statement.
Thousand Oaks, California-based Amgen won a similar verdict in 2016, as well as a court order blocking Praluent sales, but an appeals court set aside the victory and ordered a new trial.
Also Read: Setback to Sanofi: Court refuses to quash corruption case, directs CBI to continue inquiry
Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd